Mothe, BeatrizRosas-Umbert, MiriamColl, PepManzardo, ChristianPuertas Castro, Ma. CarmenMorón-López, SaraLlano, AnuskaMiranda, CristinaCedeño, SamandhyLópez, MiriamAlarcón-Soto, YovaninnaGómez Melis, GuadalupeLangohr, KlausBarriocanal, Ana M.Toro, JessicaRuiz, IreneRovira, CristinaCarrillo, AntonioMeulbroek, MichaelCrook, AlisonWee, Edmund G.Miró Meda, José M. (José María), 1956-Clotet, Bonaventura, 1953-Valle, MartaMartínez Picado, Francisco JavierHanke, TomásBrander, ChristianMoltó, JoséB.C.N02 Study Investigators2021-02-242021-02-242020-05-061664-3224https://hdl.handle.net/2445/174259Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enrolling 15 early-treated HIV-1-infected individuals, testing the combination of the histone deacetylase inhibitor romidepsin as a latency-reversing agent and the MVA.HIVconsv vaccine. Romidepsin treatment resulted in increased histone acetylation, cell-associated HIV-1 RNA, and T-cell activation, which were associated with a marginally significant reduction of the viral reservoir. Vaccinations boosted robust and broad HIVconsv-specific T cells, which were strongly refocused toward conserved regions of the HIV-1 proteome. During a monitored ART interruption phase using plasma viral load over 2,000 copies/ml as a criterium for ART resumption, 23% of individuals showed sustained suppression of viremia up to 32 weeks without evidence for reseeding the viral reservoir. Results from this pilot study show that the combined kick&kill intervention was safe and suggest a role for this strategy in achieving an immune-driven durable viremic control.15 p.application/pdfengcc-by (c) Mothe, Beatriz et al., 2020http://creativecommons.org/licenses/by/3.0/esVIH (Virus)VacunacióHIV (Viruses)VaccinationHIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)info:eu-repo/semantics/article7015442021-02-24info:eu-repo/semantics/openAccess32435247